Bibliografía del artículo
1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 352:804-815, 2005.
2. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol 92:946-965, 2017.
3. Damle RN, Calissano C, Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol 23:33-45, 2010.
4. Palacios F, Abreu C, Prieto D, et al. Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation. Leukemia 29:115-25, 2015.
5. Dighiero D, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 371:1017-1029, 2008.
6. Gaidano G, Rossi D. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. Hematology Am Soc Hematol Educ Program 2017:329-337, 2017.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 96:1848-1854, 1999.
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999.
9. Stamatopoulos K, Belessi C, Hadzidimitriou A, et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 106:3575-3583, 2005.
10. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 21:2442-2451, 2007.
11. Travella A, Ripollés L, Aventin A, et al. Structural alterations in chronic lymphocytic leukaemia. Cytogenetic and FISH analysis. Hematol Oncol 31:79-87, 2013.
12. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000.
13. Van Dyke DL, Werner L, Rassenti LZ, et al. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol 173:105-113, 2016.
14. Gazzola A, Mannu C1, Rossi M, et al. The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. Ther Adv Hematol 5:35-47, 2014.
15. Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29:329-336, 2015.
16. Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia 29:877-885, 2015.
17. Rosati E, Sabatini R, Rampino G, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 22:856-865, 2009.
18. Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med 26:1931-1935, 2011.
19. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood 107:2223-2233, 2006.
20. Hajdu M, Sebestyén A, Barna G, et al. Activity of the notch-signalling pathway in circulating human chronic lymphocytic leukaemia cells. Scand J Immunol 65:271-275, 2007.
21. Osborne BA. B-CLL kicks it up a Notch. Blood 22:765-766, 2009.
22. Liu N, Zhang J, Ji C. The emerging roles of Notch signaling in leukemia and stem cells. Biomark Res 1:23, 2013.
23. Rothenberg EV. T cell lineage commitment: identity and renunciation. J Immunol 186:6649-6655, 2011.
24. Rosati E, Baldoni S, De Falco F, et al. NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. Front Oncol 8:229, 2018.
25. Di Ianni M, Baldoni S, Del Papa B, et al. NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. Front Oncol 8:105, 2018.
26. Arruga F, Gizdic B, Serra S, et al. Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. Leukemia 28:1060-1070, 2014.
27. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119:521-529, 2012.
28. Gianfelici V. Activation of the NOTCH1 pathway in chronic lymphocytic leukemia. Haematologica 97:328-330, 2012.
29. Puente XS, Beà S, Valdés-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 526:519-524, 2015.
30. Abramenko IV, Bilous NI, Chumak AA, Dyagil IS, Martina ZV. Analysis of the 3'UTR region of the NOTCH1 gene in chronic lymphocytic leukemia patients. Exp Oncol 40:211-217, 2018.
31. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 208:1389-1401, 2011.
32. Zou Y, Fan L, Xia Y, et al. NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases. Cancer Med 7:1689-1696, 2018.
33. Xu ZS, Zhang JS, Zhang JY, et al. Constitutive activation of NF-? signaling by NOTCH1 mutations in chronic lymphocytic leukemia. Oncol Rep 33:1609-1614, 2015.
34. Albi E, Baldoni S, Aureli P, et al. Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome. Tumori 103:37-40, 2017.
35. Rossi D, Spina V, Forconi F, et al. Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. Int J Cancer 130:3006-3010, 2011.
36. Del Giudice I, Rossi D, Chiaretti S, et al. NOTCH1 mutations in 12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of 12 CLL. Haematologica 97:437-441, 2012.
37. Rasi S, Monti S, Spina V, Foà R, Gaidano G, Rossi D. NOTCH1 mutations in monoclonal B-cell lymphocytosis. Hematologica 97:153-154, 2012.
38. Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood 127:2122-2130, 2016.
39. Rasi S, Khiabanian H, Ciardullo C, et al. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia. Haematologica 101:135-138, 2016.
40. Fabbri G, Holmes AB, Viganotti M, et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 114:2911-2919, 2017.
41. Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 18:108-117, 2014.
42. Balatti V, Bottoni A, Palamarchuk A, et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 119:329-331, 2012.
43. Sutton LA, Young E, Baliakas P, et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Hematologica 101:959-967, 2016.
44. Dal Bo M, Del Principe MI, Pozzo F, et al. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. Ann Hematol 93:1765-1774, 2014.
45. Sportoletti P, Baldoni S, Cavalli L, et al. NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. Br J Haematol 151:404-406, 2010.
46. Sportoletti P, Baldoni S, Del Papa B, et al. A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia. Leukemia 28:436-439, 2014.
47. Guièze R, Robbe P, Clifford R, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood 126:2110-2117, 2015.
48. Putowski M, Podgórniak M, Piróg M, et al. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia. Pol Arch Intern Med 127:238-244, 2017.
49. Del Poeta G, Del Principe MI, Postorino M, et al. Apoptosis resistance and NOTCH1 mutations impair clinical outcome in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib. Blood 130(Suppl 1):261, 2017.
50. Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 32:83-91, 2018.
51. Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 123:3247-3254, 2014.
52. Rai KR, Sawitsky A. A review of the prognostic role of cytogenetic, phenotypic, morphologic, and immune function characteristics in chronic lymphocytic leukemia. Blood Cells 12:327-38, 1987.
53. Lionetti M, Fabris S, Cutrona G, et al. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol 165:629-639, 2014.
54. Palmitelli M, Stanganelli C, Stella F, et al. Analysis of basal chromosome instability in patients with chronic lymphocytic leukaemia. Mutagenesis 2019. doi: 10.1093/mutage/gez009.
55. Stanganelli C, Travella A, Bezares R, Slavutski I. Immunoglobulin gene rearrangements and mutational status in Argentinean patients with chronic lymphocytic leukemia. Clin Lymph, Myeloma Leuk 13:447-457, 2013.
56. Weissmann S, Roller A, Jeromin S, et al. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients. Leukemia 27:2393-2396, 2013.
57. Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121:1403-1412, 2013.
58. Baldoni S, Del Papa B, Dorillo E, et al. Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. Int J Cancer 143:958-970, 2018.